Effective for dates of service on and after **September 20, 2025,** the following updates will apply to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable health care services.

Genetic Testing

Prenatal Screening using Cell-free DNA

- Clarified cfDNA screening for fetal red blood cell antigens is considered not medically necessary

Carrier Screening in the Reproductive Setting

- Expanded carrier screening: Clarified that carrier screening for a single gene condition can also be medically necessary when criteria are met
- Carrier testing based on family history: Expanded criteria to include having a relative who is a documented carrier of a genetic condition

Genetic Testing for Inherited Conditions

- New testing criteria for primary mitochondrial diseases includes mtDNA genomic sequence, large-deletion, and targeted nuclear mitochondrial gene panel analysis
- Testing for retinal disorders is considered medically necessary when the general requirements or multi-gene panel criteria are met
- Clarified weakly provoking factors for venous thromboembolism in thrombophilia testing

For questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here.